Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed through a tender offer and subsequent merger, for an upfront payment of $380.00 per share in cash (enterprise value ~ $16.6 billion), plus a non-tradeable contingent value right (CVR) up to $35.00 per share based on milestones. Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.

Johnson & Johnson to Acquire Proteologix, Inc.

May 16, 2024

Biotechnology

Johnson & Johnson entered into a definitive agreement to acquire privately held biotechnology company Proteologix for $850 million in cash, with potential additional milestone payments. The deal is expected to close mid-year 2024 subject to antitrust clearance and customary closing conditions, expanding J&J’s bispecific antibody pipeline for immune-mediated diseases including atopic dermatitis and asthma.

Jazz Pharmaceuticals Acquires Chimerix for About $935 Million

March 5, 2025

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire Chimerix in an all-cash transaction valued at approximately $935 million (about $8.55 per share). The deal is expected to close in the second quarter of 2025, pending customary closing conditions, including tender of shares in a tender offer.

Johnson & Johnson Acquires Yellow Jersey Therapeutics from Numab for $1.25B

May 28, 2024

Biotechnology

Johnson & Johnson agreed to acquire Yellow Jersey Therapeutics, a wholly owned spin-off of Numab Therapeutics, for $1.25 billion in cash to obtain global rights to NM26, a Phase‑2‑ready bispecific antibody for atopic dermatitis. The deal was announced May 28, 2024 (Numab/ Novo Holdings) and completed in July 2024; J&J will develop, manufacture and commercialize NM26 globally.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.